Enovis Corporation ENOV NYSE · Healthcare · United States
$28.56 +1.20% +$0.34
Summary
45 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Revenue grew by 13% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 13% a year. For the next fiscal year analysts expect revenue to grow by 3.9%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $527.4M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 19.3 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 12
- Hold 3
- Sell 0
Today's price within the analysts' price targets
The average target of $36.33 is 27% above today's price. 80% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2021By product
- Fabrication Technology 63%
- Medical Technology 37%
By region
- UNITED STATES 59%
- Foreign 41%
Fabrication Technology brings in 63% of revenue. Medical Technology grew fastest, by 15% a year.
Segments in detail